Table 2 Potential financial burden of CM patients at different disease stages from diagnosis up to 3 years of follow up under the HMO perspective
From: Cutaneous melanoma: cost of illness under Brazilian health system perspectives
Stage | Outpatient visit office | Laboratory exam | Imaging exam | Surgery/ pathological analysis | Cancer drugs | TOTAL | |||||
|---|---|---|---|---|---|---|---|---|---|---|---|
(HMO) | (R$a) | % | (R$) | % | (R$) | % | (R$) | % | (R$) | % | (R$) |
0 | 832 | 26.0% | 0 | 0.0% | 0 | 0.0% | 2321 | 74% | 0 | 0,0% | 3153 ± 514 |
IA, MBLV | 1327 | 3.5% | 723 | 1.9% | 14,515 | 38.4% | 15,557 | 41% | 5797.11 | 15.2% | 37,921 ± 6192 |
IA, MBHV | 1327 | 3.4% | 723 | 1.9% | 14,515 | 37.6% | 15,557 | 40% | 6604.87 | 17,1% | 38,729 ± 6324 |
IA, WBLV | 1327 | 3.5% | 723 | 1.9% | 14,515 | 38.5% | 15,557 | 42% | 5264.82 | 14,1% | 37,389 ± 6105 |
IA, WBHV | 1327 | 3.4% | 724 | 1.8% | 14,515 | 36.4% | 15,557 | 40% | 7220.08 | 18,4% | 39,345 ± 6425 |
IB, MBLV | 1370 | 1.8% | 837 | 1.1% | 20,318 | 27.0% | 26,769 | 36% | 25,327.32 | 34,1% | 74,263 ± 12,185 |
IB, MBHV | 1369 | 1.8% | 834 | 1.1% | 20,271 | 26.2% | 26,769 | 34.5% | 28,164.08 | 36,4% | 77,409 ± 12,640 |
IB, WBLV | 1371 | 1.9% | 838 | 1.2% | 20,324 | 28.2% | 26,769 | 37% | 22,866.88 | 31,7% | 72,169 ± 11,785 |
IB, WBHV | 1370 | 1.7% | 836 | 1.0% | 20,277 | 25.8% | 26,769 | 33% | 30,782.24 | 38,5% | 80,036 ± 13,069 |
II, MBLV | 1797 | 1.2% | 1257 | 0.8% | 28,357 | 18.2% | 26,769 | 17% | 97,858.77 | 62,8% | 156,042 ± 25,481 |
II, MBHV | 1791 | 1.2% | 1245 | 0.7% | 28,189 | 17.0% | 26,769 | 16% | 108,325.88 | 65,1% | 166,322 ± 27,160 |
II, WBLV | 1798 | 1.2% | 1259 | 0.9% | 28,379 | 19.9% | 26,769 | 18% | 87,442.74 | 60,0% | 145,65 ± 23,784 |
II, WBHV | 1796 | 1.0% | 1255 | 0.7% | 28,220 | 16.3% | 26,769 | 15% | 117,899.63 | 67,0% | 175,942 ± 28,731 |
rIII, MBLV | 2868 | 0.6% | 3173 | 0.7% | 64,561 | 13.2% | 17,753 | 3,6% | 399,290.29 | 81,9% | 487,646 ± 28,731 |
rIII, MBHV | 2843 | 0.5% | 3121 | 0.6% | 63,823 | 12.2% | 17,753 | 3,4% | 435,395.04 | 83,3% | 522,937 ± 79,632 |
rIII, WBLV | 2875 | 0.7% | 3188 | 0.7% | 64,715 | 14.9% | 17,753 | 4,1% | 345,670.52 | 79,6% | 434,204 ± 85,395 |
rIII, WBHV | 2873 | 0.5% | 3183 | 0.6% | 64,073 | 11.5% | 17,753 | 3,2% | 469,099.15 | 84,2% | 556,983 ± 70,905 |
IV*, MBLV | 2022 | 0.3% | 4208 | 0.6% | 63,169 | 8.6% | 4797 | 0.6% | 660,997.50 | 89,9% | 735,195 ± 120,056 |
IV*, MBHV | 1951 | 0.3% | 4061 | 0.6% | 60,850 | 8.5% | 4797 | 0.6% | 643,017.51 | 90,0% | 714,677 ± 116,706 |
IV*, WBLV | 2083 | 0.4% | 4332 | 0.8% | 64,476 | 12.3% | 4797 | 0.90% | 460,343.78 | 85,6% | 536,033 ± 87,533 |
IV*, WBHV | 2161 | 0.3% | 4493 | 0.5% | 65,142 | 7.6% | 4797 | 0.60% | 774,093.01 | 91,0% | 850,686 ± 138,916 |